Intestinal CD103(+)CD4(+) and CD103(+)CD8(+) T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up

BACKGROUND: The integrin CD103 is proposed to be a potential therapeutical target in inflammatory bowel disease (IBD), as it can form a heterodimeric integrin with β7 (Etrolizumab, anti-β7 integrin) on epithelial T cells. Therefore, we aimed to study the frequencies of different intestinal CD103(+)T...

Descripción completa

Detalles Bibliográficos
Autores principales: Roosenboom, Britt, Wahab, Peter J, Smids, Carolijn, Groenen, Marcel J M, van Koolwijk, Elly, van Lochem, Ellen G, Horjus Talabur Horje, Carmen S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Basic Science Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701511/
https://www.ncbi.nlm.nih.gov/pubmed/30918941
http://dx.doi.org/10.1093/ibd/izz049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701511/
https://www.ncbi.nlm.nih.gov/pubmed/30918941
http://dx.doi.org/10.1093/ibd/izz049

Ejemplares similares